TAKEDA PHARMACEUTI (TKPYY)

28.09
OTC Markets
Prev Close 27.64
Day Low/High 27.88 / 28.12
52 Wk Low/High 22.79 / 31.29
Exchange OTC Markets
Shares Outstanding 1582.14B
Market Cap 43.72B
Div & Yield N.A. (N.A)

Latest News

The Boston Globe Names Takeda Pharmaceuticals U.S.A., Inc. A Top Place To Work For 2017

The Boston Globe Names Takeda Pharmaceuticals U.S.A., Inc. A Top Place To Work For 2017

Annual Award Spotlights Takeda's Local Workforce Talent and Commitment to Enhancing Employee Development

The Chicago Tribune Names Takeda Pharmaceuticals U.S.A., Inc. A Workplace Achiever Of The Chicago Area 2017 Top Workplaces Award

The Chicago Tribune Names Takeda Pharmaceuticals U.S.A., Inc. A Workplace Achiever Of The Chicago Area 2017 Top Workplaces Award

Takeda's Commitment to Investing in Deerfield Operations Yields Positive Employee Survey Results

Takeda Donates $100,000 To Local, Regional Charities As Part Of Company's Takeda Cares Day Event

Takeda Donates $100,000 To Local, Regional Charities As Part Of Company's Takeda Cares Day Event

Company also announces investment in its Deerfield campus;

Takeda Welcomes The Honorable Susana Mendoza As Guest Speaker At Deerfield Headquarters To Celebrate Company's Commitment To Latino Culture

Takeda Welcomes The Honorable Susana Mendoza As Guest Speaker At Deerfield Headquarters To Celebrate Company's Commitment To Latino Culture

Company Expands Efforts To Celebrate Its Diverse & Inclusive Culture During Hispanic Heritage Month

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Takeda Acquires Ariad Pharmaceuticals in $5.2 Billion Deal

Takeda Acquires Ariad Pharmaceuticals in $5.2 Billion Deal

Shares of Ariad Pharmaceuticals soared Monday after Japan's Takeda Pharmaceutical offered to buy the leukemia drug maker.

A Very Happy New Year for Investors in Japan

A Very Happy New Year for Investors in Japan

The Nikkei 225 closed with a gain for 2016, making a run of five consecutive higher year-end closes -- the first since the 1990 bubble.

SEC Discloses Correspondence Over Valeant's Accounting Practices

SEC Discloses Correspondence Over Valeant's Accounting Practices

The SEC has released correspondence between the agency and Valeant over concerns about its tax accounting and non-GAAP reporting measures.

How to Trade Wednesday's Most Active Stocks -- Chesapeake Energy, American Eagle, More

How to Trade Wednesday's Most Active Stocks -- Chesapeake Energy, American Eagle, More

Here's a technical look on how to trade some of the most active stocks on the market today.

Valeant Plummets on Reports of Salix Takeover Breakdown

Valeant Plummets on Reports of Salix Takeover Breakdown

Valeant shares fell Wednesday on news that talks with Takeda to take over Valeant's Salix unit have broken down.

Buy These 4 Stocks and Beat Biotech's Slump

Buy These 4 Stocks and Beat Biotech's Slump

Brad Loncar, CEO of Loncar Investment said don't throw in the towel on biotech stocks yet.

Four Stellar Stocks to Beat the Biotech Slump

Four Stellar Stocks to Beat the Biotech Slump

Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum

Will Takeda Pharmaceutical (TKPYY) Stock Be Helped By Pursuit of $15 Billion in U.S. Deals?

Will Takeda Pharmaceutical (TKPYY) Stock Be Helped By Pursuit of $15 Billion in U.S. Deals?

Takeda Pharmaceuticals (TKPYY) CEO Christophe Weber said the company is exploring deals outside of Japan, particularly in the U.S.

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.

Stocks Inch Higher as Yellen Hints at Summer Rate Hike

Stocks Inch Higher as Yellen Hints at Summer Rate Hike

Stocks inch higher by mid-afternoon Friday as Federal Reserve Chair Janet Yellen suggest the central bank could implement another rate hike this summer.

Analysts Differ On Impact Of Valeant's Rejected Takeover Bid

Analysts Differ On Impact Of Valeant's Rejected Takeover Bid

Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.

Tourmaline Fact Sheet

Tourmaline Fact Sheet

Takeda Pharmaceutical Company Limited ( TSE: 4502) today announced that the U.